Abcuro
Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.
$66MSeries D
Role not disclosedMG
Mass General Brigham Ventures
Activity from announced rounds
Activity in this selectionstout-street-capital-0ab0c4ce
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $70.8M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionViolet Therapeutics
Develops first-in-class small molecule therapies for neurodegenerative disease via glial cell signaling platform
$4.8MSeed+
Role not disclosed